Semaglutide (Glp-1 Receptor Agonist) Injectable Solution

Form: Injectable solution (prefilled pen)

Strength: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 2 mg/0.5 mL

Reference Brands: Ozempic(EU & US)

Category: Diabetes

Semaglutide, a GLP-1 receptor agonist available as an injectable solution (e.g., Ozempic, Wegovy), is FDA-approved in the USA for type 2 diabetes and chronic weight management in adults. It requires Boxed Warnings for potential thyroid C-cell tumors and must meet GMP, labeling, and post-marketing surveillance standards. In the EU, semaglutide is centrally approved by the EMA for the same indications, with stringent requirements for Risk Management Plans (RMPs) and pharmacovigilance reporting. Ongoing clinical safety and batch quality oversight are essential in both markets. Explore compliant supply options at Pharmatradz.com.